Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.40 – $15.15
39% from low
Exchange
OTC Link
OS
CURALEAF HLDGS INC
No one on the platform currently holds CURLF.
No tracked institution reports a position in CURLF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-06-05 | 1-for-3reverse |
No one on the platform has traded CURLF yet.
$MSOS For all the chart experts out there 🤓 $CURLF $GTBIF and $TRLV are all tight as shit. It'll take like a 4% move on them to send MSOS into a new breakout. Come this Monday, there is no set timeline on when the ALJ needs to make their recommendation ( which is probably already written ) then it heads to Cole for the final sign off ( who was appointed by Trump ). This can quite literally pop off at any minute after Monday. Trying to time it is a fool's game at this point. You either believe and get positioned, or wait for confirmation and likely miss a massive initial move. This entire game can ( and will ) change at the snap of a finger. Best part is, you can't halt the OTC 🥵🥹🤤
View on StockTwits ↗$CURLF https://stratcann.com/news/curaleaf-takes-takeover-bid-directly-to-aurora-shareholders/ df
View on StockTwits ↗$MSOS Dragging $CURLF down on next to no volume to keep the lid on, for now...
View on StockTwits ↗$CURLF https://businessofcannabis.com/curaleafs-aurora-bid-is-a-fight-for-europes-cannabis-crown/
View on StockTwits ↗$CURLF How long will it takt GTBIF, TRLV or any other MSO to get to the international exposure level of CURLF??
View on StockTwits ↗$HITI Great interview with TDR. Here's what stood out. SSS back in positive. Remexian 10 tons in Q3, market share above 14% and climbing. Germany forecasted to grow from 200-250 tons today to 400-600, potentially 800. 229 stores. Q3 earnings Sept 14th — new records across revenue, gross profit and EBITDA. Low end exceeds the highest analyst estimate. UK entry: within the next few quarters. US entry: as soon as legally possible. Meanwhile Curaleaf bids US$4.00 for Aurora — a lowball. Fair value US$5.50-8.00. Aurora has EU distribution in DE, PL, UK. No debt. US$149M cash. Now look at $HITI: ✅ 2.2x more revenue than Aurora ✅ +30% YoY (Aurora: -9%) ✅ #1 Germany via Remexian — on a market growing to 800 tons ✅ 229 stores + 5M loyalty members ✅ UK + US optionality not priced in ✅ P/S 0.38x Fair value today: US$5.50-8.00. Before UK and US. "Something's got to give." — Raj Grover $MSOS $CURLF $ACB
View on StockTwits ↗$CURLF https://www.cannabisbusinesstimes.com/us-states/new-jersey/news/15832426/judge-rules-federal-law-preempts-nj-cannabis-labor-peace-mandate-deals-curaleaf-victory
View on StockTwits ↗$CURLF $ACB What the dizzle? https://thenewsground.com/fbi-investigated-curaleaf-for-corruption-and-money-laundering/
View on StockTwits ↗$CURLF https://www.cultivated.news/p/curaleaf-ceo-boris-jordan-defends-hostile-aurora-bid-we-wanted-to-be-friendly vb
View on StockTwits ↗$MSOS $CURLF $TRLV $GTBIF $TLRY U.S. Multi-State Operators (MSOs), tracked by funds like the AdvisorShares Pure US Cannabis ETF, are outperforming Canadian producer Tilray Brands because U.S. regulatory changes directly eliminate heavy tax burdens and unlock domestic banking for American operators, while Tilray lacks direct U.S. THC operations and struggles with broader profitability and narrow margins. Beware of the unconscionable Tilray scammers and rabidly optimistic pumptards. "All truth passes through three stages: First, it is ridiculed; second, it is violently opposed; and third, it is accepted as self-evident."
View on StockTwits ↗420 with CNW - CDC Researchers Find More Heavy Cannabis Users are Visiting ERs $CURLF $CURA.CN https://ibn.fm/MNNsf #cannabis #CDC
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +5.9% | $-0.23 | $-0.31–$-0.04 | — | 3 |
| 2027 | $1.5B | +7.5% | $-0.52 | $-0.72–$-0.27 | — | 3 |
| 2028 | $1.6B | +9.1% | $-0.09 | $-0.09–$-0.09 | — | 1 |
| 2029 | $1.7B | +9.5% | $0.15 | $0.14–$0.15 | 61.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.17 | $0.05 | +130.1% |
| 2026-05-05 | $-0.24 | $0.27 | +212.5% |
| 2026-02-26 | $-0.08 | $-0.05 | +37.5% |
| 2025-11-05 | $-0.07 | $-0.06 | +14.3% |
| 2025-08-06 | $-0.07 | $-0.06 | +14.3% |
| 2025-05-08 | $-0.07 | $-0.07 | +0.0% |
| 2025-03-03 | $-0.06 | $0.02 | +133.3% |
| 2024-11-06 | $-0.06 |
| $-0.07 |
| -16.7% |
| $2.4B |
| — |
| HMDCFHUTCHMED (China) Limited | $2.16 | +0.00% | $1.9B | — |
| HTSUFHisamitsu Pharmaceutical Co., Inc. | $29.00 | +0.00% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry